EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY-NC-ND 4.0

Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk

Jennifer L Alejo iD, Jake D Kim iD, Teresa P Y Chiang iD, Robin K Avery iD, Andrew H Karaba iD, Alexa Jefferis iD, Daniel S Warren iD, Allan B Massie iD, Aaron A R Tobian iD, Dorry L Segev iD, William A Werbel iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14913 ↗

At a glance

Beobachtungsstudie in Clinical Transplantation, 2023. Written by Jennifer L Alejo and 10 co-authors. Institution: Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Major MEDLINE topics: COVID-19, Pre-Exposure Prophylaxis, Organ Transplantation. Cited 9 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIAID NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Tixagevimab and Cilgavimab (T + C) is authorized for pre‐exposure prophylaxis (PrEP) against Coronavirus Disease 2019 (COVID‐19) in solid organ transplant recipients (SOTRs), yet patient‐reported outcomes after injection are not well described. Furthermore, changes in risk tolerance after T + C PrEP have not been reported, of interest given uncertain activity against emerging Omicron sublineages.

Methods

Within a national prospective observational study, SOTRs who reported receiving T + C were surveyed for 3 months to ascertain: (1) local and systemic reactogenicity, (2) severe adverse events with focus on cardiovascular and alloimmune complications, and (3) breakthrough COVID‐19, contextualized through (4) changes in attitudes regarding COVID‐19 risk and behaviors.

Results

At 7 days postinjection, the most common reactions were mild fatigue (29%), headache (20%), and pain at injection sites (18%). Severe adverse events were uncommon; over 3 months of follow‐up, 4/392 (1%) reported acute rejection and one (.3%) reported a myocardial infarction. Breakthrough COVID‐19 occurred in 9%, 16–129 days after receiving full dose (300/300 mg) T + C, including two non‐ICU hospitalizations. Most surveyed SOTRs (65%) felt T + C PrEP was likely to reduce their COVID‐19 risk, and 70% reported increased willingness to engage in social activities such as visiting friends. However, few felt safe to return to in‐person work (20%) or cease public mask‐wearing (15%).

Conclusions

In this prospective study of patient‐reported outcomes, T + C was well tolerated with few serious events. Several COVID‐19 breakthroughs were reported, notable as most SOTRs reported changes in risk tolerance after T + C. These results aid counseling of SOTRs regarding real‐world safety and effectiveness of T + C.

Subjects

MeSH terms (MEDLINE)

COVID-19Pre-Exposure ProphylaxisOrgan TransplantationHumansProspective StudiesTransplant RecipientsAntibodies, Monoclonal

Author keywords

EvusheldOmicronSARS-CoV-2breakthroughsafety

Substances

cilgavimabAntibodies, Monoclonaltixagevimab

Authors and institutions

  • Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Surgery, New York University Grossman School of Medicine, New York, New York, USA.
  • Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID profiles: Jennifer L Alejo, Jake D Kim, Teresa P Y Chiang, Robin K Avery, Andrew H Karaba, Alexa Jefferis, Daniel S Warren, Allan B Massie, Aaron A R Tobian, Dorry L Segev, William A Werbel

Funding

  • NIAID NIH HHS
  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Allergy and Infectious Diseases

Cite

APA

Alejo, J. L., Kim, J. D., Chiang, T. P. Y., Avery, R. K., Karaba, A. H., Jefferis, A., Warren, D. S., Massie, A. B., Tobian, A. A. R., Segev, D. L., & Werbel, W. A. (2023). Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. Clinical Transplantation. https://doi.org/10.1111/ctr.14913

Vancouver

Alejo JL, Kim JD, Chiang TPY, Avery RK, Karaba AH, Jefferis A, et al. Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. Clinical Transplantation. 2023. doi:10.1111/ctr.14913

BibTeX
@article{Alejo2023,
  author = {Alejo, Jennifer L and Kim, Jake D and Chiang, Teresa P Y and Avery, Robin K and Karaba, Andrew H and Jefferis, Alexa and Warren, Daniel S and Massie, Allan B and Tobian, Aaron A R and Segev, Dorry L and Werbel, William A},
  title = {Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14913}
}
Start for free →